These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12419481)

  • 41. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
    Raj R; Bhatti JS; Badada SK; Ramteke PW
    Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels.
    Hayashi T; Koba S; Ito Y; Hirano T
    Lipids Health Dis; 2017 Jan; 16(1):21. PubMed ID: 28125987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus].
    Fábryová L; Cagán S
    Bratisl Lek Listy; 1998; 99(3-4):138-45. PubMed ID: 9919742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin resistance and lipid metabolism.
    Howard BV
    Am J Cardiol; 1999 Jul; 84(1A):28J-32J. PubMed ID: 10418856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
    Soedamah-Muthu SS; Chang YF; Otvos J; Evans RW; Orchard TJ;
    Diabetologia; 2003 May; 46(5):674-82. PubMed ID: 12743701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.
    Kempen HJ; Gomaraschi M; Simonelli S; Calabresi L; Moerland M; Otvos J; Jeyarajah E; Kallend D; Wijngaard PLJ
    Atherosclerosis; 2016 Dec; 255():17-24. PubMed ID: 27816804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Copeptin predicts coronary artery disease cardiovascular and total mortality.
    Tasevska I; Enhörning S; Persson M; Nilsson PM; Melander O
    Heart; 2016 Jan; 102(2):127-32. PubMed ID: 26661323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship of fibroblast growth factor 23 and fetuin--A to coronary atherosclerosis.
    Akin F; Celik O; Altun I; Ayca B; Diker VO; Satılmıs S; Sahin C
    J Diabetes Complications; 2015; 29(4):550-5. PubMed ID: 25772252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
    Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
    Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of diabetic dyslipidemia.
    Garg A
    Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The physiology of lipoproteins.
    Tulenko TN; Sumner AE
    J Nucl Cardiol; 2002; 9(6):638-49. PubMed ID: 12466789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipids and lipoproteins in patients with type 2 diabetes.
    Krauss RM
    Diabetes Care; 2004 Jun; 27(6):1496-504. PubMed ID: 15161808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
    de Vries R; Borggreve SE; Dullaart RP
    Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic epidemiology of dyslipidaemia and atherosclerosis.
    Austin MA
    Ann Med; 1996 Oct; 28(5):459-63. PubMed ID: 8949979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introduction: New insight into understanding the relation of type 2 diabetes mellitus, insulin resistance, and cardiovascular disease.
    Hsueh WA
    Am J Cardiol; 2003 Aug; 92(4A):1J-2J. PubMed ID: 12957320
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.